The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Durable complete responses to PD-1 blockade alone in mismatch repair deficient locally advanced rectal cancer.
 
Andrea Cercek
Stock and Other Ownership Interests - Haystack Oncology
Consulting or Advisory Role - Bayer; Daiichi Sankyo/Astra Zeneca; G1 Therapeutics; GlaxoSmithKline; Incyte; Janssen; Merck; Seagen
Research Funding - GlaxoSmithKline; Seagen
Patents, Royalties, Other Intellectual Property - Hepatic arterial infusion with FUDR for colorectal liver metastases with DPD (Inst); Hepatic arterial infusion with FUDR for colorectal liver metastases with DPD (Inst); Neoadjuvant PD1 blockade in mismatch repair deficient solid tumors (Inst)
 
Jenna Cohen Sinopoli
No Relationships to Disclose
 
Jinru Shia
Consulting or Advisory Role - PAIGE.AI
 
Jill A. Weiss
No Relationships to Disclose
 
Lindsay Temple
No Relationships to Disclose
 
Jesse Joshua Smith
Consulting or Advisory Role - Foundation Medicine; GlaxoSmithKline; Guardant Health
Other Relationship - Johnson & Johnson/Janssen
 
Leonard B. Saltz
Consulting or Advisory Role - Genor BioPharma
 
Maria Widmar
No Relationships to Disclose
 
Gerard Fumo
No Relationships to Disclose
 
Santiago Aparo
No Relationships to Disclose
 
Paul Bernard Romesser
Employment - Memorial Sloan-Kettering Cancer Center
Consulting or Advisory Role - EMD Serono; Faeth Therapeutics; Natera
Research Funding - X-RAD Therapeutics (Inst)
(OPTIONAL) Uncompensated Relationships - Anal Cancer Foundation; HPV Alliance
 
Henry S. Walch
No Relationships to Disclose
 
Mitesh Patel
No Relationships to Disclose
 
Vetri Sudar Jayaprakasam
No Relationships to Disclose
 
Tae-Hyung Kim
No Relationships to Disclose
 
Philip Paty
No Relationships to Disclose
 
Mithat Gonen
Travel, Accommodations, Expenses - Genentech
 
Julio Garcia-Aguilar
Stock and Other Ownership Interests - Intuitive surgical
Honoraria - Intuitive Surgical; Johnson & Johnson
Consulting or Advisory Role - Intuitive Surgical; Johnson & Johnson; Medtronic
 
Martin R. Weiser
Consulting or Advisory Role - Precisca
Patents, Royalties, Other Intellectual Property - UpToDate Section Editor
 
Luis A Diaz
Leadership - Epitope Diagnostics; Jounce Therapeutics; Personal Genome Diagnostics
Stock and Other Ownership Interests - Amgen (I); Delfi Diagnostics; Epitope Diagnostics; Four Paws; Jounce Therapeutics; Kinnate Biopharma; Neophore; Personal Genome Diagnostics; Seer; Thrive Earlier Detection Corp; Zydecom
Consulting or Advisory Role - Four Paws; Kinnate Biopharma; Merck; Neophore; Personal Genome Diagnostics; Seer; Zydecom
Research Funding - Merck (Inst)
Patents, Royalties, Other Intellectual Property - EP-2912468-B1 - Papanicolaou test for ovarian and endometrial cancers; EP-3322824-A1 - Detection of tumor-derived dna in cerebrospinal fluid; US-2005202465-A1 - Thymidylate synthase gene and metastasis; US-2010041048-A1 - Circulating Mutant DNA to Assess Tumor Dynamics; US-2013323167-A1 - Detecting and treating solid tumors through selective disruption of tumor vasculature; US-2014227271-A1 - Somatic mutations in atrx in brain cancer; US-2015252415-A1 - Arid1b and neuroblastoma; US-2015344970-A1 - Personalized Tumor Biomarkers; US-2016208340-A1 - TERT Promoter Mutations in Urothelial Neoplasia; US-2016273049-A1 - Systems and methods for analyzing nucleic acid (Inst); US-2017016075-A1 - Neoantigen analysis (Inst); US-2017267760-A1 - Checkpoint Blockade and Microsatellite Instability; US-2018086832-A1 - Hla-restricted epitopes encoded by somatically mutated genes; US-2018135044-A1 - Non-unique barcodes in a genotyping assay (Inst); US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018258490-A1 - Assaying ovarian cyst fluid; US-9976184-B2 - Mutations in pancreatic neoplasms; WO-2010118016-A2 - Digital quantification of dna methylation; WO-2012094401-A2 - Genes frequently altered in pancreatic neuroendocrine tumors; WO-2018071796-A2 - Compositions and methods for identifying functional anti-tumor t cell responses
Other Relationship - Blackstone; Innovatus Capital Partners